Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

Use of lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) to predict relapse in patients with diffuse large B-cell lymphoma (DLBCL). Background: Inflammatory bowel disease ...

Please provide your email address to receive an email when new articles are posted on . Mirikizumab, a monoclonal antibody poised to become first-in-class treatment for ulcerative colitis, has the ...

Among biologic agents, vedolizumab (Entyvio) and ustekinumab (Stelara) are associated with lower rates of infection-related hospitalizations than anti-tumor necrosis factor (TNF) agents in older ...

The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for cases where a patient may not be appropriate for a TNF blocker, drugmaker ...

Senior man has stomachache Researchers compared the difference in overall health care utilization in patients with IBD who started anti-TNF therapy 2 years vs more than 2 years postdiagnosis. Early ...

In a study, veterans who used TNF blockers to treat inflammatory bowel disease had an increased risk for kidney function decline. Anti-tumor necrosis factor (anti-TNF) therapy may increase the risk ...

Patients with both inflammatory bowel disease (IBD) and obesity starting on new biologic therapies do not face an increased risk for hospitalization, IBD-related surgery, or serious infection, reveals ...

Disruption of the gut microbiome is a feature of both conditions, but experts do not know if this gut dysbiosis underlies the link between the two diseases. A new study comparing the microbiomes of ...

The AS and IBD Link Can AS Cause IBD? Treatments Lifestyle Remedies When to See a Doctor Ankylosing spondylitis (AS) is a chronic form of inflammatory arthritis that causes pain and stiffness in the ...